UnitedHealth Group remains a Buy with strong fundamentals and a decade-low valuation.

UnitedHealth Group (UNH) is rated a Buy as its fundamentals improve and its price-to-earnings ratio hits a decade low at 19.95, despite being cheaper than peers. Key focus areas for Q3 include commercial cost trends, star ratings, cash flow guidance, and Optum’s performance amid a shrinking insured customer base. The company’s free cash flow yield is at a nine-year high of 7.1%, supported by strong revenue growth and margins that highlight its scale advantages. Risks include potential antitrust actions from the Department of Justice and star rating downgrades that could affect revenue and margin recovery in 2028.

UnitedHealth Group shares are trading at USD 372.80 on Pluang as of Oct 05, 2026 19:11 WIB, showing a modest 0.24% increase in one day. The stock's market capitalization stands at $327.80 billion, reflecting its significant presence in the health sector. Investors hold the stock for an average of 97 days on Pluang, indicating a medium-term interest in its performance.